COVID-19 Variants of Concern

COVID-19 Microchapters
Home
Long COVID
Frequently Asked Outpatient Questions
Frequently Asked Inpatient Questions
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating COVID-19 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Vaccines
Secondary Prevention
Future or Investigational Therapies Ongoing Clinical Trials
Case Studies
Case #1
COVID-19 Variants of Concern On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of COVID-19 Variants of Concern All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on COVID-19 Variants of Concern
CDC on COVID-19 Variants of Concern
COVID-19 Variants of Concern in the news
Blogs on COVID-19 Variants of Concern
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for COVID-19 Variants of Concern

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:

Variants of Concern

WHO Label	Name	Countries of Earlier Detection	Time of First Detection	Spike Protein Substitutions	BEI Reference Isolate	Properties	Rate of Spread	Severe Illness and Mortality	Vaccine	Treatments
Alpha B.1.1.7	20I/501Y.V1	United Kingdom	September 2020	69del, 70del, 144del, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*)	NR-54000external icon	Approximately 50% increased transmissibility Increased severity according to hospitalizations and case fatality rates Little effect on neutralization by convalescent and post-vaccination sera	High	Occur	Effective Rarely, breakthrough infections in vaccinated individuals may occur	Effective
Beta B.1.357	20H/501.V2	South Africa	September 2020	D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V	NR-55282	Approximately 50% increased transmissibility A marked decrease in the susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, other EUA monoclonal antibody treatments are available Decreased neutralization by convalescent and post-vaccination sera	High	Not common	Effective Rarely, breakthrough infections in vaccinated individuals may occur	Less effective
Gamma P.1	20J/501Y.V3	Brazil and Japan	December 2020	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I	NR-54982	A marked decrease in the susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, other EUA monoclonal antibody treatments are available Decreased neutralization by convalescent and post-vaccination sera	High	Not common	Effective Rarely, breakthrough infections in vaccinated individuals may occur	Less effective
Delta B.1.617.2	21A/S:478K	India	December 2020	T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, D950N		Increased transmissibility Decreased neutralization by some EUA monoclonal antibody treatments  Significant decrease in neutralization by post-vaccination sera	Characterized by the highest rate of spread among these variants	Characterized by higher rates of hospitalizations, severe illness, and death than other variants	Effective Rarely, breakthrough infections in vaccinated individuals may occur	Less effective